News

RESTEM Receives FDA Orphan Drug Designation for its ULSC Program for the Treatment of Polymyositis and Dermatomyositis

CORONA, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies…

1 year ago

AltruBio Announces Formation of Scientific Advisory Board

World-renowned researchers with extensive experience in immunology and autoimmune diseases join AltruBio to support scientific advancements and pipeline development Photo…

1 year ago

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision…

1 year ago

Glass House Brands Announces the Filing of Prospectus Supplement for Previously Announced At-The-Market Distribution Program

Not for distribution to United States news wire services or dissemination in the United StatesLONG BEACH, Calif. and TORONTO, Dec.…

1 year ago

FDA Authorizes Beacon’s Dreem 3S as First Sleep Wearable with Predetermined Change Control Plan, Paving the Way for Continuous Algorithm Enhancements in Sleep Monitoring

BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Beacon Biosignals is proud to announce FDA authorization of the Predetermined Change Control Plan…

1 year ago

Rakovina Therapeutics Announces Presentation at the 13th Annual Tumour Models London Summit

VANCOUVER, British Columbia, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical…

1 year ago

Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy

The sNDA submission is based on positive results from Studies 501 and 502 demonstrating CAPLYTA’s robust antidepressant efficacy and favorable…

1 year ago

Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting

SEATTLE, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to…

1 year ago

Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply

Five-year renewable agreement secures reliable cGMP rhenium-186 (Re-186) supply for late-stage clinical and commercial forecastsAUSTIN, Texas, Dec. 03, 2024 (GLOBE…

1 year ago

Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials

Tuspetinib selected for a prestigious national clinical research program for ability to target broad spectrum of AML and MDS populations…

1 year ago